Prevalence and Impact of Subclinical Thyroid Dysfunction on Mortality among Patients Presenting with Cardiovascular Events
Abstract
Objective. This study aims to determine the prevalence of subclinical thyroid dysfunction among cardiac patients at the Philippine General Hospital, and its association with mortality.
Methodology.163 adult cardiac patients were screened for subclinical thyroid dysfunction, [subclinical hyperthyroidism (SCT), subclinical hypothyroidism (SCHO), non-thyroidal illness syndrome (NTIS)]. Demographic and clinical characteristics were analyzed using ANOVA and Fisher’s exact test. Outcome considered were hospital duration, need for mechanical ventilation, inotropic support and mortality. Crude association between subclinical thyroid dysfunction and outcomes was evaluated using relative risk.
Results. Prevalence of subclinical thyroid dysfunction was 32.5% (5.5% SCT, 5.5% SCHO, and 21.5% NTIS). The risk of necessitating mechanical ventilation was about twofold higher in subclinical thyroid dysfunction compared to euthyroid patients (RR=2.64), and was highest in SCHO (RR=3.71). The risk of inotropic support was about twofold higher (RR=2.70) in SCHO compared to euthyroid patients. Overall death rate was higher in subclinical thyroid dysfunction (RR=1.86), and highest in SCHO (RR=2.47) compared to euthyroid patients.
Conclusion. There is a significant prevalence of subclinical thyroid dysfunction among hospitalized patients with cardiac disease at 32.5%. Cardiovascular risk factors are not statistically significant. We observed a trend of increased risk of requiring mechanical ventilation, inotropes and overall mortality in SCHO.
Downloads
References
Surks MI, Ortiz E, Daniels GH. Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. JAMA. 2004; 291:228-238.
Bagchi N, Brown T, Parish R. Thyroid dysfunction in adults over age 55 years. A study in an urban US community. Arch Intern Med. 1990; 150:785–787.
Parle J, Franklyn J, Cross K, Jones C. Prevalence and follow-up of abnormal thyrotropin concentrations in the elderly in the United Kingdom. Clin Endocrinol. 1991; 34:77–83.
Hollowell JG, Staehling NW, Flanders WD, Hannon Wh, Gunter Ew, Spencer Ca et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87:489-499.
De Groot LJ. Dangerous dogmas in medicine: The nonthyroidal illness syndrome. JCEM. 1999; 84(1):151-164.
Singh S, Duggal J, Molnar J, Maldonado F, Barsano CP, Arora R. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: A meta-analysis. Int J Cardiol. 2008 Mar 28; 125(1):41-8. (p.4)
Osman F, Gammage MD, Sheppard MC, Franklyn JA. Cardiac dysrhythmias and thyroid dysfunctions – the hidden menace? J Clin Endocrinol Metab 2002; 87(3):963-967.
Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002; 137:904-914.
Utiger RD. Altered thyroid function in nonthyroidal illness and surgery: To treat or not to treat? N Engl J Med. 1995; 333:1562–1563.
Iervasi G, Pingitor A, Landi P, Raciti M, Ripoli A, Scarlattini M et al. Low-T3 Syndrome a strong prognostic predictor of death in patients with heart disease. Circulation. 2003; 107:708-713.
Molinaro S, Iervasi G, Lorenzoni V, Coceani M, Landi P, Srebot V et al. Persistence of mortality risk in patients with acute cardiac diseases and mild thyroid dysfunction. Am J Med Sci. 2012; 343(1):65–70.
Dong BJ. How medications affect thyroid function. West J Med. 2000; 172:102-106.
Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman P, Feddema P, Michelangeli V. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005; 165: 2467-2472.
Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris T, Bauer DC. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med. 2005; 165:2460-2466.
Carlos-Raboca J, Jimeno CA, Kho SA, Andag-Silva AA, Jasul Jr. GV, Nicodemus, Jr. NA et al. The Philippine Thyroid Diseases Study (PhilTiDeS 1): Prevalence of thyroid disorders among adults in the Philippines. JAFES. 2012; 27 (1):27-33.
Cooper DS. Clinical practice. Subclinical hypothyroidism. N Engl J Med. 2001; 345:260 –265.
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 200; 160:526–534.
Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med. 2001; 45:512–516.)
Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10-year cohort study. Lancet. 2001; 358:861–865. (p.10)
Volzke H, Schwahn C, Wallaschofski H, Dorr M. The relation of thyroid dysfunction with all-cause and circulatory mortality: Is there a causal relationship? J Clin Endocrinol Metab, 2007; 92: 2421–2429. (p.11)
Kovacs G. Subclinical hyperthyroidism and mortality rate in geriatric patients. The thyroid and cardiovascular risk: Merck European Thyroid Symposium Berlin 2004, June 10-13.
Papazafiropoulou A, Sotiropoulos A, Kokoloki A, Kardara M, Stamataki P, Pappas S: Prevalence of thyroid dysfunction among Greek type 2 diabetic patients attending an outpatient clinic. J Clin Med Res. 2010; 2:75–78.
Sathyapalan T, Manuchehri AM, Rigby AS, Atkin SL. Subclinical hypothyroidism is associated with reduced all-cause mortality in patients with type 2 diabetes. Diabetes Care. 2010; 33(3):E37.
Palma CCSSV, Paves M, Nogueira VG, Clemente ELS, Vasconcellos MDFBMP, Pereira Jr LC. Prevalence of thyroid dysfunction in patients with diabetes mellitus. Diabetology & Metabolic Syndrome. 2013; 5:58.
Díez JJ1, Iglesias P. Subclinical hyperthyroidism in patients with type 2 diabetes. Endocrine. 2012; 42(1):157-63.
Stanicka ́ S, VondraK, Pelika ́nova ́ T, Hill PVM, Zamrazil V. Insulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapy. Clinical Chemistry and Laboratory Medicine. 2005; 43(7):715–720.
Mitrou P, Raptis SA, Dimitriadis G. Insulin action in hyperthyroidism: A focus on muscle and adipose tissue. Endocrine Reviews. 2010; 31(5): 663–679.
Sawin CT, Séller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. NEJM 1994; 331(19): 1249-1252.
Hamilton MA, Stevenson LW, Luu M, Walden JA. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol. 1990; 16(1):91-95.
Friberg L, Drvota V, Bjelak AH, Eggertsen G, Ahnve S. Association between increased levels of reverse triiodothyronine and mortality after acute myocardial infarction. Am J Med. 2001;111:699 –703.
Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000; 132: 270-278.
Wright SP, Verouhis D, Gamble G, Swedberg K, Sharpe N, Doughty RN. Factors influencing the length of hospital stay of patients with heart failure. Eur J Heart Fail (2003) 5 (2): 201-209.
Schlenker EH. Effects of hypothyroidism on the respiratory system and control of breathing: Human studies and animal models. Respir Physiol Neurobiol. 2012; 181(2):123-3.
Vanhorebeek I, De Vos R, Mesotten D, Wouters PJ, De Wolf-Peeters C, Van den Berghe G. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet. 2005; 365:53–59.
Boelen A1, Kwakkel J, Fliers E. Beyond low plasma T3: Local thyroid hormone metabolism during inflammation and infection. Endocr Rev. 2011 Oct;32(5):670-93.
Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med. 2007; 167(14):1526-1532.
Published
How to Cite
Issue
Section
License
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.
A written agreement shall be emailed to the requester should permission be granted.